Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132874 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1TSHRCASP1 | |
| SCHEMBL8546431 | 0.84 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1TSHRCASP1 | |
| SCHEMBL1015021 | 0.81 | MEN1 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL1015022 | 0.81 | MEN1 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL3659496 | 0.76 | MEN1 (0.46) | ALDH1A1KMT2AMEN1TSHRLMNA | |
| SCHEMBL14738587 | 0.76 | MEN1 (0.46) | ALDH1A1KMT2AMEN1TSHRLMNA | |
| SCHEMBL2021797 | 0.76 | MEN1 (0.46) | ALDH1A1KMT2AMEN1LMNAALOX15 | |
| SCHEMBL8847188 | 0.73 | MEN1 (0.47) | ALDH1A1KMT2AMEN1TSHRCASP1 | |
| SCHEMBL4881052 | 0.72 | MEN1 (0.46) | ALDH1A1KMT2AMEN1TSHRLMNA | |
| SCHEMBL31132730 | 0.72 | MEN1 (0.42) | ALDH1A1KMT2AMEN1CYP1A2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2022-06-02 | — | — | US | disclosed |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | GALAPAGOS NV (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200165259-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2020-05-28 | — | — | US | disclosed |
| CN-111094283-A | ASK 1-inhibiting pyrrolopyrimidine and pyrrolopyridine derivatives | 加拉帕戈斯股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165259-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | IRAK1, PEAK1, MARK1 | ALDH1A1 717/4885KMT2A 3318/4885MEN1 2900/4885 |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | IRAK1, PEAK1, MARK1 | ALDH1A1 717/4885KMT2A 3318/4885MEN1 2900/4885 |
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | IRAK1, PEAK1, MARK1 | ALDH1A1 717/4885KMT2A 3318/4885MEN1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.